689 results on '"O'Donnell, James S"'
Search Results
2. von Willebrand disease
3. Examining variability in the diagnosis and management of people with bleeding disorders of unknown cause: communication from the ISTH SSC Subcommittee on von Willebrand Factor
4. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1
5. Novel functions for von Willebrand factor
6. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
7. O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies
8. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
9. Glycolytic reprogramming fuels myeloid cell-driven hypercoagulability
10. Low von Willebrand factor—unraveling an enigma wrapped in a conundrum
11. Unraveling coagulation factor–mediated cellular signaling
12. VWF–ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion
13. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor
14. Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
15. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A
16. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction
17. Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score
18. Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
19. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis
20. von Willebrand factor links primary hemostasis to innate immunity
21. Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice
22. Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement
23. Therapeutic implications of ongoing alveolar viral replication in COVID-19
24. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis
25. Examining international practices in the management of pregnant women with von Willebrand disease
26. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy
27. Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
28. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting
29. Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress
30. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis
31. Management of elective procedures in low von Willebrand factor patients in the LoVIC study
32. R1205H (Vicenza) causes conformational changes in the von Willebrand factor D′D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI
33. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis
34. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease
35. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies
36. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis
37. Low VWF: insights into pathogenesis, diagnosis, and clinical management
38. Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria
39. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
40. Investigating the clearance of VWF A‐domains using site‐directed PEGylation and novel N‐linked glycosylation
41. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies
42. Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia
43. von Willebrand factor sialylation—A critical regulator of biological function
44. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor
45. Novel therapies for hemophilia A – the role of the von Willebrand factor chaperone
46. How I treat low von Willebrand factor levels
47. Enhanced thrombin generation potential and endothelial dysfunction in chronic spontaneous urticaria
48. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels
49. Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor
50. Antithrombin inhibition using nanobodies to correct bleeding in hemophilia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.